AcelRx will try to sell investors on an $86M IPO

Despite plenty of recent evidence of investors' lukewarm appetite for biotech IPOs, AcelRx Pharmaceuticals has announced plans to try and raise $86 million in an initial offering. There's no word yet on how many shares or what price will be offered. Piper Jaffray is acting as sole book-running manager while Canaccord Genuity, Cowen and Company and JMP Securities are acting as co-managers.

AcelRx named Richard King, the former president of Tercica, as its CEO back in April. The Redwood City, CA-based company has been developing a slate of pain drugs for post-operative and breakthrough cancer pain as well as a mild sedative and boasts of a new drug platform.

A year ago, AcelRx says it successfully completed an end-of-Phase II meeting with the FDA for ARX-01, a drug/device combo that enables delivery of sufentanil by the non-invasive sublingual route. IPO planning appears to be hot again now that a slate of new offerings have hit. But several biotechs have found recently that they still face a very skeptical audience of investors. And despite an ongoing late-stage study for post-operative pain, AcelRx still has no product revenue to speak of.

- check out the AcelRx release
- here's a note from Renaissance Capital

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”